Binds Specifically-identified Oligosaccharide Structure Patents (Class 424/137.1)
-
Patent number: 8758753Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.Type: GrantFiled: March 19, 2009Date of Patent: June 24, 2014Assignee: Centro de Inmunologia Molecular (CIM)Inventors: Cristina Maria Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
-
Publication number: 20140170150Abstract: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by a Campylobacter organism.Type: ApplicationFiled: February 11, 2011Publication date: June 19, 2014Applicant: The Governors of the University of AlbertaInventors: Christine SZYMANSKI, Harald NOTHAFT
-
Publication number: 20140170151Abstract: The present invention synthetic oligo-?-(1?6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-?-(1?6)-glucosamine species having a definite number of monosaccharide units, including a set pattern of acetylated and non-acetylated residues. The invention further provides antibodies to these synthetic oligo-?-(1?6)-glucosamines as well as compositions thereof and methods for treating and preventing infections caused by bacteria expressing poly-?-(1?6)-glucosamines, such as Staphylococcus aureus.Type: ApplicationFiled: February 11, 2014Publication date: June 19, 2014Inventors: A. Stewart CAMPBELL, Obadiah J. PLANTE
-
Publication number: 20140161793Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.Type: ApplicationFiled: December 14, 2011Publication date: June 12, 2014Applicants: INSERM, INSTITUT PASTEUR, Centre National De La Recherche ScientifiqueInventors: Armelle PHALIPON, Farida NATO, Laurence MULARD, Philippe SANSONETTI, Francoise BALEUX, Frederic BELOT, Cyrille GRANDJEAN
-
Publication number: 20140161806Abstract: A specific antibody against a compound of formula (I) wherein X is O, NH, S, CH2; L is a linker that is a divalent spacer; A is an adjuvant or carrier that is an immunogenic molecule or an immunogenic particle; and wherein bonds between linker and saccharide moiety and between linker and carrier are of covalent type; wherein the linker L presents a chemical structure suitable to space the saccharide moiety and the carrier by 7-30 atoms when the adjuvant/carrier A is a biomacromolecule or by 19-30 atoms when the adjuvant/carrier A is a metallic nanoparticle; wherein the carrier/adjuvant A can be selected among a macromolecule, a macrocycle, a dendrimer, a liposome, a nanoparticle, an oligosaccharide featuring from two to five monosaccharidic units or cells like dendritic cells.Type: ApplicationFiled: February 18, 2014Publication date: June 12, 2014Applicant: AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (Italian Hospital)Inventors: Cristina Nativi, Lucio Toma, Barbara Richichi, Carlotta Lunghi
-
Publication number: 20140154257Abstract: Present invention is directed to materials and methods useful in diagnosing gut derived advanced glycation end-products (“Fru-AGEs”) associated with asthma, juvenile arthritis and other pro-inflammatory chronic diseases. Fru-AGEs arise from the interaction [fructosylation] between elevated gastro-intestinal excess free fructose and other food/bio-molecules including peptides, proteins, lipids, lipo/glycoproteins and others in the digestive tract. Such Fru-AGEs may further interact with moieties of the systemic circulation of those at risk [fructose malabsorbers], i.e. with acute phase proteins, heat shock proteins, immunoglobulins, esRAGE, and sRAGE. Specification describes methods to identify and/or make such excess-free-fructose derived immunogens, i.e.Type: ApplicationFiled: June 3, 2013Publication date: June 5, 2014Inventor: Luanne Robalo DeChristopher
-
Patent number: 8703129Abstract: Disclosed herein are antibodies or antigen-binding portions thereof directed against extended Type I chain antigens, in particular extended Type I chain glycosphingolipids, and the uses of the antibodies or antigen-binding portions thereof in the diagnosis, amelioration, treatment or prevention of diseases or disorders in mammals, including humans, resulting from or associated with the improper activity/metabolism or the presence of extended Type I chain antigens, in particular extended Type I chain glycosphingolipids.Type: GrantFiled: March 29, 2012Date of Patent: April 22, 2014Assignee: GlycoNex, Inc.Inventors: Tong-Hsuan Chang, Jerry Ting, Mei-Chin Yang, Liahng-Yirn Liu, Shu-Yen Chang, Chia-Hao Chang
-
Patent number: 8697069Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.Type: GrantFiled: December 20, 2011Date of Patent: April 15, 2014Assignees: Dana-Farber Cancer Institute, The Brigham and Women's Hospital, Inc.Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
-
Publication number: 20140093504Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.Type: ApplicationFiled: January 31, 2012Publication date: April 3, 2014Applicant: Her Majesty The Queen In Right Of Canada, as repre sented by the Minister of National DefenceInventors: Wei-Gang Hu, Laurel M Negrych, Damon Chau, Junfei YIN, Scott J. Jager, John W. Cherwonogrodzky
-
Publication number: 20140086923Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: ApplicationFiled: March 29, 2012Publication date: March 27, 2014Applicants: INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, INSERM (Institut National de la Sante et de la Recherche Medicale, CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD - LYON 1Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Patent number: 8658168Abstract: This invention discloses monoclonal antibodies (MAbs) which have little or no signaling activity as monomers become potent anti-tumor agents when they are converted into homoconjugates. The homoconjugates exert anti-growth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and does not require an Fc portion. These conjugates are potent, anti-tumor agents.Type: GrantFiled: April 8, 2002Date of Patent: February 25, 2014Assignee: The Board of Regents of The University of Texas SystemInventors: Maria-Ana Ghetie, Jonathan W. Uhr, Ellen S. Vitetta
-
Publication number: 20140050731Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: ApplicationFiled: August 13, 2013Publication date: February 20, 2014Applicant: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Publication number: 20140044721Abstract: The present invention lies in the field of new cancer therapies, more precisely in the field of antiangiogenic compounds. It notably concerns anti-Gb3 antibodies having specific CDR sequences, as well as the use of anti-Gb3 antibodies not coupled to a therapeutic molecule in the treatment of diseases associated with angiogenesis, such as solid tumors.Type: ApplicationFiled: February 7, 2012Publication date: February 13, 2014Applicants: INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE, UNIVERSITE DE NANTESInventors: François Paris, Stephane Birkle, Ariane Desselle, Jacques Aubry, Marie-Hélène Gaugler, Denis Cochonneau, Tanguy Chaumette
-
Publication number: 20140037633Abstract: The invention relates to the compositions of synthetic oligo-?-(1?6)-2-amino-2-deoxy-D-glucopyranosides conjugated to carriers, and methods for making and use same.Type: ApplicationFiled: June 21, 2013Publication date: February 6, 2014Inventors: Gerald B. Pier, Nikolay Nifantiev, Yury Tsvetkov, Marina Gening
-
Patent number: 8637025Abstract: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.Type: GrantFiled: March 4, 2004Date of Patent: January 28, 2014Assignee: Immuron LimitedInventors: Roy Michael Robins-Browne, Grant Thomas Rawlin, Gottfried Lichti
-
Publication number: 20140017247Abstract: A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment.Type: ApplicationFiled: May 28, 2013Publication date: January 16, 2014Applicants: CDA Royalty Investors, LLC, Glenveigh Pharmaceuticals, LLCInventors: Charles David Adair, Yuping Wang
-
Publication number: 20130309237Abstract: Described herein are antigen binding proteins that bind to pathogenic mycobacteria-derived Mannose-Capped Lipoarabinomannan (ManLAM) and methods and kits for using and making the antigen binding proteins. Also described herein are antigen binding proteins that bind to the alpha 1-2 linkage mannose caps of ManLAM, antigen binding proteins that bind to a mannose cap with up to three alpha 1-2 linked mannose residues, and antigen binding proteins that bind to LAM with a mannose sugar capping motif.Type: ApplicationFiled: January 25, 2012Publication date: November 21, 2013Applicants: DSO NATIONAL LABORATORIES, NATIONAL UNIVERSITY OF SINGAPOREInventors: Paul Anthony Macary, Conrad En Zuo Chan, Brendon John Hanson, Markus R. Wenk
-
Publication number: 20130295100Abstract: The present invention relates to a method for predicting the risk of developing acute kidney injury in a subject from which a biological sample is obtained comprising: detecting the presence of at least one genomic single nucleotide polymorphism (SNP) selected from the group of: ADD1 rs4961 Trp [allelic genotype GT or TT], ADD2 rs4984 [allelic genotype CT or TT], HS-D3B1 rs2236780 [allelic genotype GG], LSS rs914247 [allelic genotype AA], MDR1 rs1045642 [allelic genotype TC or CC], SLC8A1 rs1 1893826 [allelic genotype AA], TRPC6 rs7925662 [allelic genotype CC] from said biological sample, wherein the presence of said allelic genotype is predictive of the risk of developing acute kidney injury.Type: ApplicationFiled: November 21, 2011Publication date: November 7, 2013Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Paolo Manunta, Lorena Citterio, Giovanni Guglielmo Landoni, Elena Giovanna Bignami, Elisabetta Messaggio
-
Publication number: 20130295161Abstract: The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osteoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked ?-gal epitopes for induction of an inflammatory response localized within or surrounding damaged tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects.Type: ApplicationFiled: April 2, 2013Publication date: November 7, 2013Inventor: Uri Galili
-
Publication number: 20130295099Abstract: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by a Campylobacter organism.Type: ApplicationFiled: February 11, 2011Publication date: November 7, 2013Applicant: The Governors of the University of AlbertaInventors: Christine SZYMANSKI, Harald NOTHAFT
-
Publication number: 20130287691Abstract: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.Type: ApplicationFiled: July 2, 2013Publication date: October 31, 2013Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou
-
Patent number: 8568718Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: GrantFiled: June 8, 2011Date of Patent: October 29, 2013Assignee: Bioalliance C.V.Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
-
Patent number: 8552156Abstract: The present invention provides an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: GrantFiled: June 13, 2011Date of Patent: October 8, 2013Assignees: Kyowa Hakko Kirin Co., Ltd, Kyushu University, National University CorporationInventors: Shin-ichiro Takayanagi, Hitomi Tomura, Tomonori Tawara, Yoshimasa Inagaki, Tsuguo Kubota, Koichi Akashi, Yoshikane Kikushige
-
Publication number: 20130243751Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.Type: ApplicationFiled: December 14, 2011Publication date: September 19, 2013Inventors: Armelle PHALIPON, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
-
Patent number: 8518403Abstract: A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.Type: GrantFiled: July 15, 2005Date of Patent: August 27, 2013Assignee: Amgen Research (Munich) GmbHInventors: Patrick Hoffmann, Silke Mittelstrass, Jens Hennecke, Tobias Raum
-
Patent number: 8501183Abstract: The present invention relates to a method of inducing an immune response to a parasite utilizing an immunogenic composition comprising a glycosylphosphatidylinositol (“GPI”) inositolglycan domain or its derivative or equivalent. The present invention is useful as a prophylactic and/or therapeutic treatment for microorganism infections of mammals such as parasite infections and particularly infection by Plasmodium species. The invention also provides a method of monitoring, or qualitatively or quantitatively assessing an immune response to a microorganism such as a parasite.Type: GrantFiled: September 22, 2011Date of Patent: August 6, 2013Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventor: Louis Schofield
-
Publication number: 20130195873Abstract: Immunogenic compositions that contain haptens consisting of carbohydrate moieties are useful to induce an immune response to provide antibodies to epitopes contained in CA215 and also to elicit an immune response to cancers expressing these epitopes.Type: ApplicationFiled: July 14, 2011Publication date: August 1, 2013Applicant: Vancouver Biotech LTD.Inventor: Chi-Yu Gregory Lee
-
Publication number: 20130171147Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 002-H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: July 4, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder
-
Publication number: 20130164216Abstract: Provided in the present invention are an aberrantly glycosylated integrin, AG-?3?1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-?3?1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.Type: ApplicationFiled: August 12, 2011Publication date: June 27, 2013Applicant: Institute Of Biophysics, Chinese Academy Of SciencesInventors: Chong Li, Zusen Fan, Honglian Zhang, Zhonghua Dai, Haidong Tang, Jun Chen
-
Publication number: 20130156696Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.Type: ApplicationFiled: May 27, 2011Publication date: June 20, 2013Applicant: CASE WESTERN RESERVE UNIVERSITYInventors: John R. SCHREIBER, Kulwant KAUR
-
Publication number: 20130142789Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.Type: ApplicationFiled: January 22, 2013Publication date: June 6, 2013Applicant: Medarex, Inc.Inventor: Medarex, Inc.
-
Publication number: 20130129736Abstract: The present invention relates to a method for the in vitro determination of the presence of or a predisposition of a patient to the development of cancer. In the method according to the invention, the presence of a marker is determined in a biological sample of the patient, said marker being selected from a) the amino acid sequence SEQ ID Nr. 2 from the sequence protocol that is provided, or b) a nucleic acid that encodes the amino acid sequence with the SEQ ID Nr. 2. The invention further relates to the amino acid and the encoding nucleic acid and to the use thereof in diagnostics and for molecular therapeutic approaches.Type: ApplicationFiled: January 29, 2013Publication date: May 23, 2013Applicant: Eberhard-Karls-Universit.t Tubingen Universit. tsklinikumInventor: Eberhard-Karls-Universit.t Tubingen Universit.tsklinikum
-
Publication number: 20130108636Abstract: The invention provides engineered antibody domains (eAds), a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the same. Nucleic acids encoding eAd and/or polypeptide or the fusion protein thereof, as well as compositions or cells comprising the eAd, polypeptide, fusion protein, or nucleic acid also are provided.Type: ApplicationFiled: May 20, 2011Publication date: May 2, 2013Inventors: Dimiter S. Dimitrov, Weizao Chen
-
Publication number: 20130108624Abstract: The present invention relates to a novel glycan marker of cancer and monoclonal antibodies against it. Furthermore, novel glycan markers and their use in the detection and monitoring of cancerous cells and cancer-associated or specific antibody signatures are described.Type: ApplicationFiled: December 3, 2012Publication date: May 2, 2013Applicants: Imperial College of London, The Board of Trustees of the Leland Stanford Junior UniversityInventors: The Board of Trustees of the Leland Stanford Junior University, Imperial College of London
-
Publication number: 20130101587Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: ApplicationFiled: September 14, 2012Publication date: April 25, 2013Applicant: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Patent number: 8414889Abstract: Anti-?-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to ?-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans and Aspergillus fumigatis infections. The antibodies of the present invention are not specific for ?-1,6-glucan.Type: GrantFiled: December 20, 2011Date of Patent: April 9, 2013Inventors: Antonio Cassone, Antonella Torosantucci
-
Publication number: 20130078251Abstract: The invention provides anti-MCSP antibodies and methods of using the same.Type: ApplicationFiled: August 21, 2012Publication date: March 28, 2013Inventors: Olivier Freytag, Guy Georges, Ekkehard Moessner, Olaf Mundigl, Gérald Tuffin, Pablo Umana
-
Publication number: 20130052197Abstract: The invention provides a therapeutic agent for autoimmune diseases, particularly type 1 diabetes and rheumatoid arthritis, as well as a method of preparing the therapeutic agent and a method of treating an autoimmune disease with the therapeutic agent. The therapeutic agent is an anti-CD98 antibody that does not inhibit amino acid transport of CD98 but has a suppressive action on T lymphocyte activation, a suppressive action on cell adhesion mediated by fibronectin, as well as an OVA antibody production suppressive action in OVA immunization model.Type: ApplicationFiled: March 25, 2011Publication date: February 28, 2013Applicant: THE UNIVERSITY OF TOKUSHIMAInventor: Koji Yasutomo
-
Publication number: 20130052198Abstract: The present invention provides particular anti-inflammatory factors, compositions containing them, methods of making, identifying, and/or characterizing them, and methods of using them. In some embodiments, provided factors are expressed by human bone marrow stromal cells (MSC). In some embodiments, provided factors are characterized by an ability, when contacted with mammalian leukocytes in culture, to alter production of at least one inflammatory or anti-inflammatory agent by the mammalian leukocytes. In some embodiments, provided factors include GALNT1 polypeptides, LGALS3BP polypeptides, MFAP5 polypeptides, PENK polypeptides and/or HAPLN1 polypeptides. In some embodiments, provided factors are useful in the inhibition of inflammatory agents, in the promotion of anti-inflammatory agents, and/or for the treatment of subjects suffering from or susceptible to a disease, disorder or condition characterized by inflammation.Type: ApplicationFiled: March 29, 2011Publication date: February 28, 2013Applicants: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: John Miles Milwid, Biju Parekkadan, Martin Leon Yarmush, Matthew LI
-
Publication number: 20130045207Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype G and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: February 21, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA PHARMA CO., LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Publication number: 20130034557Abstract: Cancer-associated O-glycopeptide combination epitopes derived from the VNTR of MUC1 are disclosed. Autoantibodies present in human sera target the combination epitopes and are reduced or absent in cancer patients. The epitopes are useful as therapeutic and immunoprophylactic cancer vaccines. Monoclonal antibodies directed against the epitopes are also useful as immunotherapeutics for treatment and prevention of cancer. Diagnostic methods using the epitopes and antibodies are also disclosed.Type: ApplicationFiled: April 15, 2011Publication date: February 7, 2013Applicant: EZOSE SCIENCES, INC.Inventors: Shin-Ichiro Nishimura, Takahiko Matsushita, Yoshiaki Miura
-
Publication number: 20130034556Abstract: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by a Campylobacter organism.Type: ApplicationFiled: February 11, 2011Publication date: February 7, 2013Applicant: The Governors of the University of AlbertaInventors: Christine Szymanski, Harald Nothaft
-
Publication number: 20130022603Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype I and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 24, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA KAISHA, LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Publication number: 20130022604Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype B and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 24, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA PHARMA CO., LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Publication number: 20130022602Abstract: The invention is directed to an improved method to manufacture virus for use in vaccine by culturing infected cells that have been modified to overexpress miR-144. The invention is also directed to manipulating the activity or level of miR-144 in subjects in order to modulate the antiviral and immune response systems.Type: ApplicationFiled: July 5, 2012Publication date: January 24, 2013Inventors: Carrie M. Rosenberger, Alan A. Aderem
-
Publication number: 20130004499Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype E and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 3, 2013Applicants: SYMPHOGEN A/S, Meiji Seika Pharma Co., Ltd.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Jun Saito, Hiroshi Nagaso, Masashi Kumagai, Yasuyo Hagiwara
-
Publication number: 20130004500Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype A and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 3, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA PHARMA CO., LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Patent number: 8329635Abstract: The present invention relates to new compounds useful for the stimulation of the production of antibodies. Said compounds comprises a saccharidic tumor antigen and a polymeric scaffold. The present invention also encompasses conjugated compounds useful in ELISA assay for the selection of antibodies against saccharidic antigens.Type: GrantFiled: June 19, 2007Date of Patent: December 11, 2012Assignee: Bracco Imaging S.p.A.Inventors: Fulvio Uggeri, Cristiana Campa, Sergio Paoletti, Anna Coslovi, Alfonso Colombatti, Carla Danussi
-
Patent number: 8323644Abstract: A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a yeast beta-glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal. The above therapeutic composition may further comprise antitumor antibodies or cancer vaccine composition, wherein the antitumor activities of the antitumor antibodies or the cancer vaccine composition are enhanced by the yeast glucan.Type: GrantFiled: January 17, 2007Date of Patent: December 4, 2012Assignees: Sloan-Kettering Institute for Cancer Research, Biotec Pharmacon ASAInventors: Nai-Kong V. Cheung, Rolf Einar Engstad
-
Publication number: 20120294864Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: ApplicationFiled: May 31, 2012Publication date: November 22, 2012Applicant: TRACON PHARMACEUTICALS, INC.Inventors: Charles Theuer, Maximiliano Vasquez